Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + GemCis Neoadjuvant Therapy for Resectable ICC
NCT05672537Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jan 2023; status: recruiting.
02
Drugs
durvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05672537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672537.